32337-97-6

Usage

Uses

Used in Pharmaceutical Industry:
1-CHLORO-2-IODO-3-NITRO-BENZENE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Industry:
In the agrochemical sector, 1-CHLORO-2-IODO-3-NITRO-BENZENE serves as an intermediate in the production of agrochemicals, aiding in the creation of substances that protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
1-CHLORO-2-IODO-3-NITRO-BENZENE is utilized as a reagent in organic synthesis, particularly for the preparation of substituted benzene derivatives, which are essential in various chemical reactions and product development.
Used in Research and Development:
1-CHLORO-2-IODO-3-NITRO-BENZENE is also employed in research and development settings for studying chemical reactions and exploring new methods of synthesis, further expanding its applications in the scientific community.

Upstream product

• 769-11-9 2-chloro-6-nitroaniline 
• 615-41-8 2-iodochlorobenzene 
• 7697-37-2 nitric acid 
• 121-73-3 3-Nitrochlorobenzene 
• 602-02-8 2,3-dinitrochlorobenzene 

Downstream Products

• 573764-31-5 3-iodo-4-chloroaniline 
• 561320-80-7 1-chloro-2-(3-methylbut-2-enyl)-3-nitrobenzene 
• 70237-25-1 3-chloro-2-iodobenzenamine 
• 882023-24-7 2-oxo-1,2,3,4-tetrahydroquinoline-5-carbonitrile 
• 72995-15-4 5-chloro-3,4-dihydro-2(1H)-quinolinone 

Relevant academic research and scientific papers

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones

Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 that bind reversibly to the active site with submicromolar potency. Structure-activity relationships in the 50 derivatives of the lead molecule 2,5-dihydroxy-3-(1H-indol-3-yl)[1,4]benzoquinone show interesting and consistent trends identifying features required for inhibition of all three isoforms of Cdc25. The compounds do not show time-dependent inhibition, indicating that they form neither covalent adducts with nor oxidize the active site thiol. Our best compounds, 2,5-dihydroxy-3-(7-farnesyl-1H- indol-3-yl)[1,4]benzoquinone and 2,5-dihydroxy-3-(4,6-dichloro-7-farnesyl-1H-indol-3-yl)[1,4]- benzoquinone, are competitive with substrate for the active site and yield Kis of 640 and 470 nM, respectively. Binding of the indolylhydroxyquinones is diminished by three, but not by six other, specific mutations in the active site region. Additionally, the flexible C-terminal tail required for binding of protein substrate is also required for binding derivatives with hydrophobic modifications at the 7-position. The indolyldihydroxyquinones compete effectively with the protein substrate for Cdc25 in vitro and lead to rapid cell death in vivo. Thus, the indolyldihydroxyquinones will serve as useful lead molecules for drug discovery and further cell-based studies on the role of Cdc25s in cell cycle control.

4 AND 5-Halo substituted 2-indanamine compounds

2-Indanamine compounds having 4 and 5-halo substituents are inhibitors of phenylethanolamine N-methyltransferase.